| Albertville Family Medicine Llc | |
|
201 W Main St Albertville AL 35950-1627 | |
| (256) 929-9074 | |
| Not Available |
| Full Name | Albertville Family Medicine Llc |
|---|---|
| Speciality | Family Medicine |
| Location | 201 W Main St, Albertville, Alabama |
| Authorized Official Name and Position | Monica Hagood (REGISTERED NURSE) |
| Authorized Official Contact | 2566771320 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Albertville Family Medicine Llc 201 W Main St Albertville AL 35950-1627 Ph: (256) 251-2012 | Albertville Family Medicine Llc 201 W Main St Albertville AL 35950-1627 Ph: (256) 929-9074 |
| NPI Number | 1154008480 |
|---|---|
| Provider Enumeration Date | 06/29/2023 |
| Last Update Date | 10/25/2023 |
| Medicare PECOS PAC ID | 4587028691 |
|---|---|
| Medicare Enrollment ID | O20230907003399 |
News Archive
A paper by Columbia Mailman School's John Rowe, MD, Julius Richmond Professor of Health Policy and Aging, in the journal Health Affairs outlines the challenges we face as the U.S. becomes an "aging society."
Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today confirmed that the opportunities for its Rev Vac safety syringe became even more significant with the August 31 announcement of close competitor Retractable Technologies, Inc. ("Retractable Technologies").
Barrett's epithelium is recognized as a complication of erosive esophagitis and is the pre-malignant condition for adenocarcinoma of the esophagus.
Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).
Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154008480 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Douglas Christopher Ginas |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629059456 PECOS PAC ID: 7911920343 Enrollment ID: I20101021000622 |
News Archive
A paper by Columbia Mailman School's John Rowe, MD, Julius Richmond Professor of Health Policy and Aging, in the journal Health Affairs outlines the challenges we face as the U.S. becomes an "aging society."
Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today confirmed that the opportunities for its Rev Vac safety syringe became even more significant with the August 31 announcement of close competitor Retractable Technologies, Inc. ("Retractable Technologies").
Barrett's epithelium is recognized as a complication of erosive esophagitis and is the pre-malignant condition for adenocarcinoma of the esophagus.
Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).
Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.
› Verified 2 days ago
| Provider Name | Eric Hagood |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205375318 PECOS PAC ID: 2567731037 Enrollment ID: I20170627002648 |
News Archive
A paper by Columbia Mailman School's John Rowe, MD, Julius Richmond Professor of Health Policy and Aging, in the journal Health Affairs outlines the challenges we face as the U.S. becomes an "aging society."
Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today confirmed that the opportunities for its Rev Vac safety syringe became even more significant with the August 31 announcement of close competitor Retractable Technologies, Inc. ("Retractable Technologies").
Barrett's epithelium is recognized as a complication of erosive esophagitis and is the pre-malignant condition for adenocarcinoma of the esophagus.
Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).
Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.
› Verified 2 days ago
News Archive
A paper by Columbia Mailman School's John Rowe, MD, Julius Richmond Professor of Health Policy and Aging, in the journal Health Affairs outlines the challenges we face as the U.S. becomes an "aging society."
Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today confirmed that the opportunities for its Rev Vac safety syringe became even more significant with the August 31 announcement of close competitor Retractable Technologies, Inc. ("Retractable Technologies").
Barrett's epithelium is recognized as a complication of erosive esophagitis and is the pre-malignant condition for adenocarcinoma of the esophagus.
Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).
Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.
› Verified 2 days ago
Outside The Box Healthcare Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5730 Us Highway 431, Albertville, AL 35950 Phone: 256-907-9700 Fax: 256-907-9724 | |
New Life Family Medicine Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1011 Horton Road, Albertville, AL 35950 Phone: 256-677-1475 | |
First Choice Family Medicine Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 431a N Carlisle St, Albertville, AL 35950 Phone: 256-601-1654 | |
William Alexander Nixon Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 11491 Us Highway 431, Albertville, AL 35950 Phone: 256-505-6826 Fax: 256-582-1100 | |
Medical Asset Group, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3442 Us Highway 431, Albertville, AL 35950 Phone: 256-907-9000 Fax: 256-907-9003 | |
John Christopher Brewer Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 11491 Us Highway 431, Ste. D, Albertville, AL 35950 Phone: 256-891-5102 Fax: 256-891-5103 |